GAITHERSBURG, Md., May 6 /PRNewswire/ -- MedImmune today announced that it has enhanced its leadership team to guide the company's expanded product pipeline in the United States and abroad as well as the core scientific research that underpins this development. Jacqueline Hall has been appointed global vice president, product development team leadership; Lorin Roskos, Ph.D. has been appointed vice president and global head of pharmacokinetics (PK), pharmacodynamics (PD), and bioanalysis in translational sciences and Beth Wensley has been appointed vice president, project management. In addition, Erik-Jan Dekker, Ph.D. joined the organization as vice president, international regulatory affairs, vaccines and Reginald Seeto, M.D., joins as vice president, global strategic marketing and portfolio management.
"It is imperative that we have strong leaders who can channel the continued growth of our product portfolio, particularly as we seek to build out the organization globally," said David M. Mott, chief executive officer and president. "Jacqui, Lorin, Beth, E-J and Reg have the innate talent, industry experience and drive for results that will contribute to MedImmune's continued leadership in biologics."
Based at MedImmune's Cambridge, UK site, Ms. Jacqueline Hall is
accountable for the strategic leadership of global product development
teams that are responsible for the generation and execution of development
plans for biologics products. She joined Cambridge Antibody Technology
(CAT), now MedImmune, in 2006 as vice president, project management.
Previously, Ms. Hall served as project leader at GlaxoSmithKline where she
was responsible for the strategic development of product candidates from
selection through to market launch. She has also held positions at
SmithKline Beecham, Pharmaco-LSR and Schering-Plough. Ms. Hall has a
first-class honors degree in chemistry from Imperial College of Science and
Technology/Birbeck College, London and a diploma
Copyright©2008 PR Newswire.
All rights reserved